FULC — Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Market
- Employees: 45
- Website: https://www.fulcrumtx.com
Latest SEC filings for FULC
- SCHEDULE 13G/A — 2026-08-14
- SCHEDULE 13G — 2026-08-03
- 10-Q — 2026-07-30
- 3 — 2026-07-15
- SCHEDULE 13G/A — 2026-07-15
- SCHEDULE 13G — 2026-06-25
- SCHEDULE 13G — 2026-06-25
- 8-K — 2026-06-25
- 8-K — 2026-06-11
- SCHEDULE 13G — 2026-06-10
Latest FULC news
- — Kaplan Fox is Investigating Claims Against Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors (newsfilecorp.com)
- — Kaplan Fox Encourages Fulcrum Therapeutics, Inc. (FULC) Investors Who Suffered Losses to Learn About Their Legal Rights (newsfilecorp.com)
- — Kaplan Fox Investor Alert: Fulcrum Therapeutics, Inc. (FULC) Investigated for Possible Securities Law Violations (newsfilecorp.com)
- — Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) and its Board for Possible Securities Law Violations (newsfilecorp.com)
- — FULCRUM LAUNCHES CERTIFICATE AUTOMATION, DOUBLING THE TIME ITS PLATFORM GIVES BACK TO ACCOUNT MANAGERS (prnewswire_financial)
- — Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of a Pending Securities Investigation (newsfilecorp.com)
- — Are FULC, TCBK, LXP Obtaining Fair Deals for their Shareholders? (prnewswire_financial)
Educational tool only — not investment advice.